Evidence map›Paper›PMID 31222165›Full record

ArticleScientific reports2019

Combating viral contaminants in CHO cells by engineering innate immunity.

Austin W T Chiang, Shangzhong Li, Benjamin P Kellman, Gouri Chattopadhyay, Yaqin Zhang, Chih-Chung Kuo, Jahir M Gutierrez, Faezeh Ghazi, Hana Schmeisser, Patrice Ménard and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Fantastic genes and where to find them expressed in CHO.Computational and structural biotechnology journal · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. CRISPR Technologies in Chinese Hamster Ovary Cell Line Engineering.International journal of molecular sciences · 2023
    Review
  7. Review
  8. Article
  9. Article
  10. mSphere · 2021
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Austin W T ChiangDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, 92093, USA.
Shangzhong LiThe Novo Nordisk Foundation Center for Biosustainability at the University of California, San Diego, La Jolla, CA, 92093, USA.
Benjamin P KellmanDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0002-0780-6096
Gouri ChattopadhyayCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA.
Yaqin ZhangCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA.
Chih-Chung KuoDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, 92093, USA.
Jahir M GutierrezDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, 92093, USA.
Faezeh GhaziDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, 92093, USA.
Hana SchmeisserViral Pathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, 20892, USA.
Patrice MénardThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Hørsholm, Denmark.
Sara Petersen BjørnThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Hørsholm, Denmark.
Bjørn G VoldborgThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Hørsholm, Denmark.
Amy S RosenbergCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA.
Montserrat PuigCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA. Montserrat.puig@fda.hhs.gov.ORCID http://orcid.org/0000-0001-8641-5706
Nathan E LewisDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, 92093, USA. nlewisres@ucsd.edu.
Foundation Center · USNovo Nordisk Foundation · DKUnited States Food and Drug Administration · USNational Institutes of Health · USUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viral contamination in biopharmaceutical manufacturing can lead to shortages in the supply of critical therapeutics. To facilitate the protection of bioprocesses, we explored the basis for the susceptibility of CHO cells to RNA virus infection. Upon infection with certain ssRNA and dsRNA viruses, CHO cells fail to generate a significant interferon (IFN) response. Nonetheless, the downstream machinery for generating IFN responses and its antiviral activity is intact in these cells: treatment of cells with exogenously-added type I IFN or poly I:C prior to infection limited the cytopathic effect from Vesicular stomatitis virus (VSV), Encephalomyocarditis virus (EMCV), and Reovirus-3 virus (Reo-3) in a STAT1-dependent manner. To harness the intrinsic antiviral mechanism, we used RNA-Seq to identify two upstream repressors of STAT1: Gfi1 and Trim24. By knocking out these genes, the engineered CHO cells exhibited activation of cellular immune responses and increased resistance to the RNA viruses tested. Thus, omics-guided engineering of mammalian cell culture can be deployed to increase safety in biotherapeutic protein production among many other biomedical applications.

Indexed as

Genetic EngineeringImmunity, InnateIndustrial MicrobiologyAnimalsBiomarkersCHO CellsCricetulusDrug ResistanceHost-Pathogen InteractionsInterferon Type IPoly I-CRNA VirusesSignal TransductionSTAT1 Transcription FactorVirus ReplicationBiomarkersInterferon Type IPoly I-CSTAT1 Transcription Factor

Identifiers

PMID31222165
PMCPMC6586939
OpenAlexW2952752862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.